Neurology India
Open access journal indexed with Index Medicus
  Users online: 771  
 Home | Login 
  About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe Etcetera Contact  
  Navigate Here 
 Search
 
  
 Resource Links
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (440 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this Article
   References

 Article Access Statistics
    Viewed473    
    Printed4    
    Emailed0    
    PDF Downloaded14    
    Comments [Add]    

Recommend this journal

 


 
Table of Contents    
COMMENTARY
Year : 2017  |  Volume : 65  |  Issue : 1  |  Page : 121-122

Histological spectrum of oligodendroglial tumors: Only a subset shows 1p/19q codeletion


Department of Neuropathology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India

Date of Web Publication12-Jan-2017

Correspondence Address:
Vani Santosh
Department of Neuropathology, National Institute of Mental Health and Neurosciences, Bengaluru - 560 029, Karnataka
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.198196

Rights and Permissions



How to cite this article:
Santosh V. Histological spectrum of oligodendroglial tumors: Only a subset shows 1p/19q codeletion. Neurol India 2017;65:121-2

How to cite this URL:
Santosh V. Histological spectrum of oligodendroglial tumors: Only a subset shows 1p/19q codeletion. Neurol India [serial online] 2017 [cited 2017 Jul 25];65:121-2. Available from: http://www.neurologyindia.com/text.asp?2017/65/1/121/198196


Until recently, histological examination has been the gold standard for establishing the diagnosis of diffuse gliomas. However, with evolving molecular genetics and awareness of biomarkers, attempts at prognostic stratification using histomolecular classification are being made with increasing success. The molecular genetic changes specific to a distinct set of gliomas have finally made their way into routine neuropathological diagnosis. The latest World Health Organization (WHO) update on central nervous system (CNS) tumors (2016) takes into account genetic testing along with histology to define an entity that is following the International Society of Neuropathology (ISN) Haarlem guidelines.[1],[2] Among the diffuse gliomas, oligodendrogliomas are known to harbour a distinctive genetic profile, i.e., the 1p19q codeletion along with isocitrate dehydrogenase (IDH) mutation.[2]

In this issue of the journal, Pai et al., present a large series of 676 cases of both pediatric (n = 18) and adult (n = 658) diffuse gliomas composed of complete or partial oligodendroglial component, which were diagnosed over a 7-year period in a single institution. This is certainly the largest series from India investigating 1p19q codeletion status. The tumors included oligodendroglioma (OD) and anaplastic oligodendroglioma (AOD), oligoastrocytoma (OA), and anaplastic oligoastrocytoma (AOA), as well as glioblastoma with an oligodendroglial component (GBM-O).[3]

The various methods of carrying out the 1p19q assay are elegantly described in this paper. As expected with the 1p19q codeletion status, the authors show a frequency of 59.24% in histological OD and AOD, 13.28% in OA and AOA, and 5.1% in GBM-O. Interestingly, in the pediatric age group, 1p/19q codeletion was seen in 25% of pure ODGs and in 10% of mixed ODGs. Thus, the authors have attempted to identify canonical ODG tumors within the broad histological spectrum of diffuse gliomas, and their results are in line with previous reports.[4],[5]

The authors state that the possible reason of a relatively lesser percentage of codeletion in their study may have been the inclusion of cases across different age groups, locations, and histological subtypes.[3] There were cases of GBM-O, of which 5.2% were codeleted, which is also similar to previous studies.[5] The authors also re-emphasize the lower frequency of p53 overexpression in pure ODG tumors, which is in agreement with the existing literature.[6] Not surprisingly, an inverse correlation between 1p/19q codeletion and p53 protein overexpression was noted. The authors conclude that adult patients with pure ODG histology, frontal location, presence of calcification, and p53 protein nonpositivity had statistically significant correlation with the 1p/19q codeletion. This observation underscores the importance of histology, which is of prime importance while evaluating any diffuse glioma.[3]

However, what is lacking in this study is the data on isocitrate dehydrogenase (IDH) mutations (which the authors admit), as well as alpha-thalassemia/mental retardation syndrome X-linked (ATRX) expression.[3] The current WHO update on CNS tumors (2016)[1] takes into consideration molecular parameters in addition to histology for defining the diffuse glioma entities. Accordingly, IDH mutation and 1p19q codeletion status have become entity defining features for ODG and AOD tumors. Loss of ATRX expression and p53 expression would help to identify diffuse astrocytomas and anaplastic astrocytomas, which are considered characteristic, even though not mandatorily required for the diagnosis.[2]

The authors also discuss the favorable prognostic benefit of 1p19q codeletion status, as noted in various studies, along with additional mutations of IDH and telomerase reverse transcriptase (TERT) promoter,[7],[8] even though they have not demonstrated the same in their study. In a previous study from our group, we demonstrated the prognostic value of the histomolecular subgroups of anaplastic grade III gliomas. In that study, anaplastic oligodendrogliomas (defined by 1p19q codeletion and IDH mutations) had the best prognosis. While the IDH-mutant anaplastic astrocytomas had an intermediate prognosis, the IDH wild-type anaplastic astrocytomas were associated with the worst prognosis; once again reiterating that molecular biomarkers in diffuse gliomas can be utilized to provide a prognostically relevant classification.[9]

From the observation in the present series and previously reported cases, pediatric oligodendrogliomas appear to be a histologic entity without a defining molecular signature. It is possible that there is more than one molecular pathway underlying the pathogenesis of this entity.[10] Here, the authors have noted 1p19q codeletion in 25% of pure ODG cases and 10% of mixed tumors. While this finding is in agreement with some of the previous studies,[11] the same was not observed in others.[12] The authors justify that these findings highlight the occurrence of the adult type (1p/19q mediated) type of ODG in the pediatric age group, especially in older children.

The present study reiterates the fact that 1p19q assay using the fluorescence in situ hybridization technique needs to be an integral part of diffuse glioma diagnosis, and that the codeletion status is an absolute requirement for the identification of canonical type of ODG. In fact, the current WHO update on CNS tumors (2016)[2] provides an algorithm for the approach to the diagnosis of diffuse gliomas, which has three tiers; histology, IDH status, and other genetic parameters which includes the 1p19q assay.

 
  References Top

1.
Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 2014;24:429-35.  Back to cited text no. 1
    
2.
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol 2016;131:803-20.  Back to cited text no. 2
    
3.
Pai T, Epari S, Desai S, Wadile A, Gupta T, Goda JS, et al. Histological spectrum of oligodendroglial tumors: Only a subset shows 1p/19q codeletion. Neurol India 2016;65:  Back to cited text no. 3
    
4.
Singh VY, Chacko G, Chacko AG, Rajshekhar V. Fluorescence in situ hybridization for 1p, 19q status in a cohort of glial neoplasms. Neurol India 2014;62:32-6.  Back to cited text no. 4
[PUBMED]  Medknow Journal  
5.
Chamberlain MC, Born D. Prognostic significance of relative 1p/19q codeletion in oligodendroglial tumors. J Neurooncol 2015;125:249-51.  Back to cited text no. 5
    
6.
Jeon YK, Park K, Park CK, Paek SH, Jung HW, Park SH. Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: A clinicopathological study using fluorescence in situ hybridization. Neuropathology 2007;27:10-20.  Back to cited text no. 6
    
7.
Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: Long-term results of RTOG 9402. J Clin Oncol 2013;31:337-43.  Back to cited text no. 7
    
8.
Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 2015;372:2499-508.  Back to cited text no. 8
    
9.
Rajmohan KS, Sugur HS, Shwetha SD, Ramesh A, Thennarasu K, Pandey P, et al. Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: Applying the 'integrated' diagnosis approach. J Clin Pathol 2016;69:686-94.  Back to cited text no. 9
    
10.
Kreiger PA, Okada Y, Simon S, Rorke LB, Louis DN, Golden JA. Losses of chromosomes 1p and 19q are rare in pediatric oligodendrogliomas. Acta Neuropathol 2005;109:387-92.  Back to cited text no. 10
    
11.
Raghavan R, Balani J, Perry A, Margraf L, Vono MB, Cai DX, et al. Pediatric oligodendrogliomas: A study of molecular alterations on 1p and 19q using fluorescence in situ hybridization. J Neuropathol Exp Neurol. 2003;62:530-7.  Back to cited text no. 11
    
12.
Myal Y, Del Bigio MR, Rhodes RH. Age-related differences in 1p and 19q deletions in oligodendrogliomas. BMC Clin Pathol 2003;3:6.  Back to cited text no. 12
    




 

Top
Print this article  Email this article
   
Online since 20th March '04
Published by Wolters Kluwer - Medknow